Boston, MA — October 2025 — QMB, an emerging leader in AI-driven MedTech SaaS, today announced the close of a $2 million seed financing round to accelerate the launch of QualiVerse®, a Regulatory Intelligence Engine that redefines how medical device innovators achieve compliance, accelerate new product development (NPD), and scale safely to market.
The round is led by The Boston Foundation's Business Equity Investment Fund and CEI Ventures, marking a major milestone for QMB as it positions itself as a category-creating company at the intersection of AI, regulatory intelligence, and MedTech innovation.
"QMB is building the category infrastructure that MedTech has been missing," said Anthony Rust, Fund Manager of the Business Equity Investment Fund. "Michel's vision is deeply informed by lived experience as both a regulator and SaaS product architect — and this is exactly the kind of entrepreneur we back to redefine industries."
"We're excited to support QMB in bringing critical innovation to the MedTech sector," said Orlando Watkins, Vice President and Chief Program Officer of The Boston Foundation. "QualiVerse® represents the type of transformative technology that not only drives business growth but also has the potential to improve patient outcomes on a global scale. This aligns perfectly with our mission to invest in companies that create meaningful economic opportunity while advancing social impact."
"CEI Ventures is proud to partner with QMB," said Shannon Bean, Principal, CEI Ventures. "We're especially proud that all current and planned jobs at QMB exceed the MIT Living Wage for Norfolk County, aligning with CEI Ventures' Good Jobs Framework and our commitment to equitable, high-quality employment. QualiVerse® is the rare platform that marries technical sophistication with impact at scale — accelerating safer devices to patients worldwide."
"Quality and regulatory are the unsung heroes of medical innovation — they safeguard lives while too often operating in the shadows," said Michel Moravia, Chairman & CEO of QMB. "With QualiVerse®, we're giving these teams the intelligent platform they deserve — a system that makes compliance not a bottleneck, but a catalyst for innovation. As both a MedTech regulatory veteran and product leader in enterprise SaaS, I know firsthand the cost of delay and the urgency of getting this right."
Building on early enterprise revenue traction and pilot interest from leading device innovators, QMB will use the seed financing to expand engineering capabilities, deepen data integrations, and advance RegTech-as-Infrastructure™ pilots with MedTech manufacturers in late 2025.
Strategic Governance
The seed round adds strategic governance from impact investors with deep healthcare and SaaS expertise:
Michel Moravia, Chairman & CEO – 15+ years in MedTech regulatory and quality
Orlando Watkins, Board Director – The Boston Foundation
Robert Bennett, Board Director – Scaled EngageSmart® to PE acquisition
Shannon Bean, Board Observer – CEI Ventures
About QualiVerse®
QualiVerse® is an AI-native enterprise platform that unifies design control, risk management, regulatory intelligence, and compliance scoring. QualiVerse® transforms standards such as ISO 13485, ISO 14971, IEC 62304, and EU MDR into a living, workflow-aware operating system. The platform delivers faster product launches, lower compliance risk, and measurable ROI across quality and regulatory functions — redefining what's possible in MedTech digital transformation.
About The Boston Foundation
Founded in 1915, The Boston Foundation is among the nation's largest and oldest community foundations, managing $1.9 billion in assets. The Foundation partners with nearly 1,000 donors to build a prosperous, equitable Greater Boston region where justice and opportunity are extended to all. Learn more at www.tbf.org.
About CEI Ventures
CEI Ventures, Inc. is a leading impact venture capital firm founded in 1994, investing in companies driving social and environmental impact. Based in Maine, CEI Ventures is wholly owned by Coastal Enterprises, Inc. (CEI), a CDFI that has deployed more than $1.6 billion to grow businesses and strengthen communities. Learn more at www.ceimaine.org/cei-ventures.
About Quality Means Business (QMB)
Quality Means Business, Inc. (QMB) builds QualiVerse®, the Regulatory Intelligence Engine for MedTech quality, regulatory, and NPD. With AI copilots, predictive analytics, and compliance-aware automation, QMB empowers innovators to launch safer, more effective devices — faster and with confidence.
Follow the journey: connect with Michel Moravia on LinkedIn for founder insights and updates from Quality in the Boardroom, QMB's podcast spotlighting leaders shaping the future of medical innovation.
Learn more at QMB.ai and QualiVerse.com.
QualiVerse Editorial
Insights and updates from the team building the future of MedTech regulatory compliance.
